



Robert Greene Sterne
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimbalà
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
Steven R. Ludwig
John M. Covert
Linda E. Horner
Robert C. Millonig
Donald J. Featherstone
Timothy J. Shea, Jr.
Michael V. Messinger
Judith U. Kim

Patrick E. Garrett
Jeffrey T. Helvey
Heidi L. Kraus
Eldora L. Ellison
Thomas C. Fiala
Donald R. Banowitz
Peter A. Jackman
Jeffrey S. Weaver
Brian J. Del Buono
Vincent L. Capuano
Virgil Lee Beason
Theodore A. Wood
Elizabeth J. Haanes
Joseph S. Ostroff
Frank R. Cottingham
Rae Lynn P. Guest
Daniel A. Klein
Jason D. Eisenberg

Michael D. Specht
Tracy L. Muller
Jon E. Wright
LuAnne M. DeSantis
Ann E. Summerfield
Helene C. Carlson
Cynthia M. Bouchez
Timothy A. Doyle
Gabry L. Longworth
Lori A. Gordon
Ted J. Ebersole
Laura A. Vogel
Bryan S. Wade
Bashir M.S. Ali
Shannon A. Carroll
Matthew E. Kelley
Michelle K. Holoubek
Marsha A. Rose*

W. Blake Coblenz*
James J. Pohl*
John T. Haran*
Mark W. Rygiel

Registered Patent Agents*
Karen R. Markowicz
Matthew J. Dowd
Katrina Yujian Pei Quach
Bryan L. Skelton
Robert A. Schwartzman
Teresa A. Colella
Victoria S. Rutherford
Simon J. Elliott
Julie A. Heider
Mita Mukherjee
Scott M. Woodhouse
Christopher J. Walsh

Liliana Di Nola-Barnes
Peter A. Socarras
Jeffrey Mills
Danielle L. Letting
Lori Brandes

Of Counsel
Edward J. Kessler
Kenneth C. Bass III
Marvin C. Guthrie

*Admitted only in Maryland
*Admitted only in Virginia
*Practice Limited to
Federal Agencies

February 21, 2006

WRITER'S DIRECT NUMBER:
(202) 772-8606
INTERNET ADDRESS:
ANNS@SKGF.COM

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Mail Stop: Amendment

Re: U.S. Utility Patent Application
Application No. 10/698,928; Filed: October 31, 2003
For: **Novel Cytarabine Monophosphate Prodrugs**
Inventors: Boyer *et al.*
Our Ref: 2358.0180002/RWE/AES

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Credit Card Payment Form (PTO-2038) in the amount of **\$180.00** to cover Information Disclosure Statement Filing fee (37 C.F.R. § 1.17(p));
2. Second Supplemental Information Disclosure Statement Under 37 C.F.R. § 1.97(c);
3. Two (2) pages of Form PTO/SB/08B citing eleven (11) documents (Documents II-JS);
4. Copies of the eleven (11) cited documents; and
5. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents
February 21, 2006
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,


STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

A handwritten signature in cursive script, reading "Ann E. Summerfield".

Ann E. Summerfield
Attorney for Applicants
Registration No. 47,982

RWE/AES:law
Enclosures

499211_1.DOC



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

BOYER *et al.*

Appl. No.: 10/698,928

Filed: October 31, 2003

For: **Novel Cytarabine Monophosphate
Prodrugs**

Confirmation No.: 2990

Art Unit: 1626

Examiner: T. Solola

Atty. Docket: 2358.0180002/RWE/AES

**Second Supplemental Information Disclosure Statement
Filing Under 37 C.F.R. § 1.97(c)**

Mail Stop Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO/SB/08B are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Second Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' First Supplemental Information Disclosure Statement filed on January 18, 2006 in connection with the captioned application. Copies of all documents cited on accompanying Form PTO/SB/08B, documents **JI-JS**, are submitted herewith.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier or later than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS

Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Second Supplemental Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection, or Notice of Allowance, or an action that otherwise closes prosecution in the application. Attached is our PTO-2038 Credit Card Payment Form in the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p).

It is respectfully requested that the Examiner initial and return copies of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.




Ann E. Summerfield
Attorney for Applicants
Registration No. 47,982

Date: February 21, 2006

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

499163_1.DOC



PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project of 07-05, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/698,928
				Filing Date	October 31, 2003
				First Named Inventor	Serge Boyer
				Art Unit	1626
				Examiner Name	Solola, Taofiq A.
Sheet	1	of	2	Attorney Docket Number	2358.0180002/RWE/AES


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T ²
	J1	BRAESS, J. <i>et al.</i> "Oral Cytarabine Octosfate in Acute Myeloid Leukemia and non-Hodgkin's Lymphoma – Phase I/II Studies and Pharmacokietics", <i>Leukemia</i> 12:1618-1626, Stockton Press (1998)	
	JJ	CHABNER, B.A., "Cytidine Analogues", in <i>Cancer Chemotherapy: Principles and Practice</i> , Lippincott Williams & Wilkins (April 1990)	
	JK	CHABNER, B.A., <i>et al.</i> , "Purification and Properties of Cytidine Deaminase from Normal and Leukemic Granulocytes", <i>Journal of Clinical Investigation</i> 53:922-931, American Society for Clinical Investigation (March 1974)	
	JL	COHEN, S.S. "The Mechanisms of Lethal Action of Arabinosyl Cytosine (araC) and Arabinosyl Adenine (araA)", <i>Cancer</i> 40:509-518, Wiley (1977)	
	JM	GRANT, S., "Biochemical Modulation of Cytosine Arabinoside", <i>Pharmac. Ther.</i> 48:29-44, Pergamon Press plc (1990)	
	JN	LEACH, W.B. <i>et al.</i> "Toxicity Studies in Mice Treated with 1-β-D-Arabinofuranosyl-cytosine (ara-C)", <i>Cancer Research</i> 29:529-535, America Association for Cancer Research (March 1969)	
	JO	PLUNKETT, W. <i>et al.</i> "Pharmacologically Directed Ara-C Therapy for Refractory Leukemia", <i>Seminars in Oncology</i> 12(2) Supp. 3:20-30, W.B. Saunders (June 1985)	
	JP	RUSTUM, Y.M., <i>et al.</i> "1-β-Arabinofuranosylcytosine in Therapy of Leukemia: Preclinical and Clinical Overview" <i>Pharmac. Ther.</i> 56:307-321, Pergamon Press Ltd. (1992)	
	JQ	SHIMMA, N. <i>et al.</i> , "The Design and Synthesis of a New Tumor-Selective Fluoropyrimidine Carbamate, <i>Capecitabine</i> " <i>Bioorganic & Medicinal Chemistry</i> 8:1697-1706, Elsevier Science Ltd. (2000)	
	JR	SUTO, T. <i>et al.</i> "The Effect of YNK-01 (an Oral Prodrug of Cytarabine) on Hepatocellular Carcinoma" <i>Seminars in Oncology</i> 24(2) Suppl 6:S6-122-S6-129, W.B. Saunders (April 1997)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Substitute for form 1449/PTO

(Use as many sheets as necessary)

Sheet	2	of	2
-------	---	----	---

Complete if Known

Application Number	10/698,928
Filing Date	October 31, 2003
First Named Inventor	Serge Boyer
Art Unit	1626
Examiner Name	Solola, Taofiq A.
Attorney Docket Number	2358.0180002/RWE/AES

NON PATENT LITERATURE DOCUMENTS

499131.1

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.